Related by context. All words. (Click for frequent words.) 78 PEG SN# 77 alvespimycin 75 ganetespib 75 INCB# [001] 74 forodesine 74 oral prodrug 73 PXD# 73 HGS ETR1 72 PRT# 72 Phase Ib study 72 AEG# 72 IMA# 72 velafermin belinostat 72 HuMax EGFr 72 huC# DM4 72 Azedra 71 phase IIa clinical 71 velafermin 71 oral ridaforolimus 71 Panzem R NCD 71 TACI Ig 71 Phase 1b trial 71 CCX# 71 CBLC# 71 Alocrest 71 PSMA ADC 71 obatoclax 71 phase IIb clinical 71 FOLOTYN ® 71 tanespimycin 71 Bezielle 71 Traficet EN 71 Phase 2a trial 71 CoFactor 71 nab paclitaxel 71 OncoVEX GM CSF 71 GALNS 71 deforolimus 70 mertansine 70 Atiprimod 70 ZYBRESTAT 70 metaglidasen 70 CRLX# 70 Golimumab 70 talactoferrin 70 Triolex 70 HGS ETR2 70 CCR9 antagonist 70 CYT# potent vascular disrupting 70 IRX 2 70 Phase Ib 70 elotuzumab 70 pomalidomide 70 pralatrexate 70 HER2 positive metastatic breast 70 IMGN# 70 YONDELIS 70 RGB # 70 enzastaurin 70 ISIS # 70 phase IIb trial 70 Chemophase 70 Phase 1b 70 Triapine 69 R#/MEM # 69 AQ4N 69 neratinib 69 Phase #/#a trial 69 Symadex 69 preclinically 69 Carfilzomib 69 Virulizin ® 69 HCD# [002] 69 IIa trial 69 OMP #M# 69 SAR# [004] 69 AeroLEF TM 69 JAK2 inhibitor 69 Sym# 69 indibulin 69 mapatumumab 69 Proxinium TM 69 evaluating tivozanib 69 Phase IIa trial 69 CD# antibody [001] 69 adecatumumab 69 Nanobody 69 NP2 Enkephalin 69 Quinamed 69 XmAb# 69 Zybrestat 69 IL# PE#QQR 69 CA4P 69 Elotuzumab 69 Exherin TM 69 HuMax CD4 69 Phase IIIb clinical 69 Pimavanserin 68 GAP #B# 68 IAP inhibitors 68 registrational 68 elacytarabine 68 OvaRex R 68 systemic RNAi therapeutic 68 cannabinor 68 glufosfamide 68 Tyrima 68 imetelstat 68 Phase Ib II 68 eniluracil 68 ALN TTR 68 Archexin 68 LY# [003] 68 PRTX 68 Trofex 68 zanolimumab 68 Sapacitabine 68 investigational humanized monoclonal antibody 68 CTAP# Capsules 68 trastuzumab DM1 T DM1 68 ongoing Phase 1b 68 sapacitabine 68 phase IIb study 68 otelixizumab 68 Panzem 68 Phase IIb trials 68 Cloretazine ® 68 MAGE A3 ASCI 68 HuLuc# 68 protein kinase inhibitor 68 AP# [003] 68 pertuzumab 68 Phase 2b Clinical Trial 68 HQK 68 CCX# B 68 Nanobody ® 68 registrational trial 68 delafloxacin 68 ALN PCS 68 vidofludimus 68 ELACYT 68 Aurexis 68 Ceflatonin 68 ALN VSP 68 TOCOSOL Paclitaxel 68 GRN# 68 PEG PAL 68 tezampanel NGX# 68 Aplidin R 68 oral picoplatin 68 ZOLINZA 68 Phase III Pivotal 68 ENMD # 68 Perifosine 68 #I TM# 68 seliciclib 68 MDV# 68 Phase 2b study 68 CEQ# 68 Phase #/#a 68 metastatic castration resistant 68 rALLy clinical trial 68 MGCD# [001] 67 CYC# 67 lintuzumab 67 ulimorelin 67 docetaxel Taxotere R 67 cilengitide 67 DAVANAT 67 JAK inhibitor 67 telaprevir VX 67 tezampanel 67 PEG Interferon lambda 67 KRN# 67 PDE4 inhibitor 67 Phase Ib clinical 67 TG# [003] 67 PROSTVAC TM 67 PDX pralatrexate 67 OXi# 67 BAY #-# 67 NGX# 67 anticancer compound 67 MEK inhibitor RDEA# 67 Bicifadine 67 phase Ib 67 Pralatrexate 67 Alpharadin 67 novel VDA molecule 67 radezolid 67 Aplidin 67 IMC A# 67 Aflibercept 67 cystinosis patients 67 Glufosfamide 67 Plicera 67 DermaVir Patch 67 investigational monoclonal antibody 67 Tezampanel 67 INT# [002] 67 Trofex TM 67 Lovaxin C 67 liposomal formulation 67 Vitaxin 67 antibody MAb 67 Pertuzumab 67 NOX E# 67 Tesetaxel 67 romidepsin 67 Diamyd ® 67 BRIM2 67 pharmacokinetic PK 67 torezolid phosphate 67 lomitapide 67 metastatic hormone refractory 67 RLY# 67 orally administered inhibitor 67 Phase 2a 67 APOPTONE 67 TASKi2 67 Allovectin 7 R 67 BCX# 67 orally bioavailable 67 L BLP# 67 sunitinib malate 67 Seliciclib 67 LE DT 67 Reolysin 67 oral FTY# 67 anti leukemic 67 Capesaris 67 BZL# 67 phase IIb 67 Tavocept 67 Thiovir 67 Fx #A 66 bardoxolone methyl 66 ATL# [001] 66 teduglutide 66 CD# CEA 66 lorvotuzumab mertansine 66 Phase #b/#a 66 HGS# 66 ZK EPO 66 cediranib 66 Allovectin 7 66 Xanafide 66 ularitide 66 thymalfasin 66 HCV protease inhibitor 66 ELND# 66 atrasentan 66 PROCHYMAL 66 DXL# 66 custirsen 66 REOLYSIN ® 66 SUCCEED trial 66 INCB# [003] 66 PEGylated interferon beta 1a 66 APTIVUS 66 MEK inhibitors 66 PCK# 66 TRO# 66 lintuzumab SGN 66 RSD# oral 66 tgAAC# 66 virus HCV protease inhibitor 66 Phase 2b trial 66 Panzem R 66 rindopepimut 66 Phase Ib clinical trials 66 PLK1 SNALP 66 Clolar ® 66 Mipomersen 66 Neuradiab 66 viral kinetic 66 riociguat 66 tiapamil 66 Cotara 66 MEK inhibitor 66 GLP toxicology studies 66 class mGluR5 inhibitor 66 isoform selective 66 pan HDAC inhibitor 66 Phase IIb clinical trials 66 CIMZIA ™ 66 GAMMAGARD 66 lesinurad 66 fosbretabulin 66 TLK# 66 EZN 66 olaparib 66 GLPG# 66 CINQUIL 66 atacicept 66 axitinib 66 XL# XL# XL# XL# 66 OvaRex ® MAb 66 Meets Primary Endpoint 66 relapsed refractory multiple myeloma 66 OMP #R# 66 AAG geldanamycin analog 66 GMX# 66 ProLindac 66 Tarceva TM 66 Exelixis XL# 66 CIMZIA TM 66 AVE# 66 optimal dosing regimens 66 Phase #b/#a clinical 66 OHR/AVR# 66 GRNVAC1 66 recurrent glioblastoma multiforme 66 ONCONASE R 66 GW# [003] 66 pharmacokinetic PK study 66 omega interferon 66 Phase IIa clinical 66 Personalized Immunotherapy 66 IMC #B 66 dose escalation 66 Amrubicin 66 Phase 2a clinical 66 Panzem NCD 66 rNAPc2 66 favorable pharmacokinetic profile 66 trastuzumab DM1 66 teriflunomide 66 MORAb 66 targeted radiotherapeutic 66 PSN# [002] 66 belinostat 66 plasma kallikrein inhibitor 66 pharmacodynamic effects 66 systemically administered 66 metastatic RCC 66 LUX Lung 66 Guanilib 66 Asentar 66 GRN#L 66 Blinatumomab 65 OMAPRO 65 Allovectin 7 ® 65 LibiGel ® 65 dose escalation trial 65 Viramidine 65 ProSavin 65 ARIKACE 65 candidate CRLX# 65 CCR5 mAb 65 Phase 2a clinical trials 65 #D#C# 65 dose escalation Phase 65 elagolix 65 Ophena TM 65 ThGRF 65 Civacir 65 RAV# 65 Annamycin 65 pharmacodynamic PD 65 p# biomarker 65 humanized anti 65 Tanespimycin 65 relapsed MM 65 budesonide foam 65 urocortin 2 65 Phase 1a 65 prostate cancer CRPC 65 XL# XL# XL# 65 castration resistant prostate cancer 65 entinostat 65 heavily pretreated 65 IND submission 65 CORT # 65 TPI ASM8 65 CD3 monoclonal antibody 65 relapsed multiple myeloma 65 nalbuphine ER 65 MyVax R 65 Cloretazine 65 EndoTAG TM -1 65 Phase 2b clinical 65 EOquin TM 65 Enzastaurin 65 dasatinib Sprycel ® 65 solithromycin 65 inhibitor RG# 65 Dapagliflozin 65 epigenetic therapies 65 galiximab 65 superficial bladder cancer 65 metastatic CRC 65 XYOTAX TM 65 brivaracetam 65 Velcade bortezomib 65 CD# monoclonal antibody 65 Azixa 65 Randomized Phase 65 Trastuzumab 65 triphendiol 65 receptor tyrosine kinase inhibitor 65 Factor VIIa 65 Insegia 65 Phenoptin 65 Advaxis Phase 65 maximally tolerated dose 65 selective androgen receptor modulator 65 Clavis Pharma 65 picoplatin 65 uric acid lowering 65 Intravenous CP 65 INCB# [002] 65 OncoVEX 65 Ozarelix 65 celgosivir 65 Cloretazine R VNP#M 65 HSP# inhibitor 65 Gliadel Wafer 65 mRCC 65 Zerenex 65 Abiraterone acetate 65 TOCOSOL Camptothecin 65 multicenter Phase II 65 TELINTRA 65 orally dosed 65 Tarvacin TM 65 Immunotherapeutic 65 Pazopanib 65 MEND CABG 65 bardoxolone 65 crizotinib PF # 65 MYDICAR ® 65 sipuleucel T 65 rFIXFc 65 depsipeptide 65 cMET 65 BRIM3 65 telomerase therapeutic 65 MEK Inhibitor 65 bevacizumab Avastin ® 65 AMD# [003] 65 dirucotide 65 oral deforolimus 65 Romidepsin 65 Amplimexon 65 regorafenib 65 JAK1 65 Hsp# inhibition 65 radiolabeled TM# 65 NEUMUNE 65 ponatinib 65 confirmatory Phase III 65 Bortezomib 65 Phase IIb Clinical Trial 65 ALN RSV# 65 TKM ApoB 65 Urocidin 65 Voreloxin 65 Laquinimod 65 MGd 65 PNP inhibitor 65 dose cohort 65 EFAPROXYN 65 ZACTIMA 65 PRESEPT 65 LEP ETU 65 phase IIa 65 Azedra TM 65 NVA# 65 ImmunoVEX HSV2 65 Menerba 65 GED aPC 65 Imprime PGG 65 RDEA# 65 Ceplene/IL-2 65 AVONEX ® 65 Androxal TM 65 TG# [001] 65 standard chemotherapy regimen 65 midstage clinical 65 MLN# 65 Angiocept 65 PNT# 65 Hepatocellular Carcinoma HCC 65 rALLy trial 64 T DM1 64 Tarvacin 64 volociximab 64 davunetide intranasal AL 64 vinca alkaloid 64 ACTEMRA TM 64 eprotirome 64 recurrent glioblastoma 64 EOquin 64 sorafenib tablets 64 TKB# 64 proteasome inhibitor 64 varespladib 64 seliciclib CYC# 64 randomized Phase IIb 64 ofatumumab 64 Marqibo 64 VitiGam 64 ostarine 64 vorinostat 64 angiogenesis inhibitor 64 EVIZON 64 trastuzumab Herceptin 64 valopicitabine 64 trastuzumab Herceptin R 64 PS# [001] 64 Valortim 64 Phase IIB 64 GFT# 64 Aryplase 64 MCSP respectively 64 aplindore 64 CRx 64 CRMD# 64 pegylated liposomal doxorubicin 64 pradefovir 64 selective modulator 64 huN# DM1 64 CINTREDEKIN BESUDOTOX 64 Safinamide 64 hematological cancers 64 nonclinical studies 64 tolerability pharmacokinetics 64 Phase Ia 64 anti amnesic 64 dexpramipexole 64 ACZ# 64 ospemifene 64 decitabine 64 leading oral taxane 64 MAXY G# 64 Rebif ® 64 lumiliximab 64 Novolimus 64 generation Hsp# inhibitor 64 MET amplification 64 initiate Phase 1b 64 investigational therapies 64 pharmacodynamic properties 64 radiation sensitizer 64 Tesmilifene 64 polymerase inhibitors 64 nitazoxanide 64 RIGScan CR 64 Vicinium TM 64 eltrombopag 64 p# inhibitor 64 ANYARA 64 Fibrillex TM 64 tolerated dose MTD 64 PEGPH# 64 ALN TTR# 64 Proellex TM 64 lucinactant 64 Metastatic Melanoma 64 initiated Phase 1b 64 BRAF inhibitor 64 pazopanib 64 paclitaxel Taxol R 64 Omacetaxine 64 Myocet 64 E1 INT TM 64 vosaroxin 64 IAP inhibitor 64 Elagolix 64 Afatinib 64 Daclizumab 64 Genz # 64 THR beta agonist 64 motesanib 64 Genasense ® oblimersen 64 erlotinib Tarceva ® 64 SPC# [001] 64 Solazed TM 64 Locteron ® 64 samalizumab 64 HuMax CD# 64 talabostat 64 PKC# 64 oral gallium 64 Restanza 64 XL# XL# 64 refractory gout 64 FOLOTYN 64 Litx 64 RNAi therapeutic targeting 64 Altastaph 64 DPX Survivac 64 refractory APL 64 VEGF Trap 64 ocrelizumab 64 Milatuzumab 64 GOUT 64 Excellarate 64 PANVAC VF 64 Panitumumab 64 Cannabinor 64 eliglustat tartrate 64 Cethrin 64 randomized discontinuation trial 64 CUSTOM III 64 LymphoStat B 64 histone deacetylase HDAC inhibitor 64 CD# expressing 64 Darusentan 64 TTF Therapy 64 Phase III Clinical Trial 64 Genasense ® 64 HDAC Inhibitor 64 immatics 64 Kahalalide F 64 AZILECT R 64 #ME# 64 hA# 64 Phase 1b clinical trials 64 Microplasmin 64 KNS # 64 HCV polymerase inhibitors 64 SCH # 64 viral kinetics 64 RG# [001] 64 castrate resistant prostate cancer 64 Locteron 64 catheter occlusion 64 Ridaforolimus 64 Telatinib 64 TBC# 64 HCV protease 64 vicriviroc 64 Alzhemed TM 64 Apoptone 64 farletuzumab 64 relapsed ovarian cancer 64 ATL/TV# 64 Troxatyl 64 PHX# 64 lenalidomide dexamethasone 64 dacetuzumab 64 ganaxolone 64 PROSTVAC VF 64 compound INCB# 64 Zenvia ™ 64 dose cohorts 64 liprotamase 64 Phase IIa trials 64 intravesical instillation 64 Valortim R 64 advanced carcinoid 64 torezolid 64 recurrent GBM 64 Angiolix 64 randomized controlled Phase 64 Marqibo TM 64 Curaxin 64 TransVax ™ 64 daclizumab 64 cetuximab Erbitux 64 bortezomib Velcade 64 investigational hepatitis C 64 DAVANAT R 64 nucleoside analog 64 dose escalation phase 64 antiangiogenic 64 APTIVUS r 64 assessing T DM1 64 Hsp# Inhibitor 64 alvimopan 64 Hedgehog Pathway Inhibitor 64 Tamibarotene 64 tramiprosate Alzhemed TM 64 plus Copegus R 64 metastatic renal cell carcinoma 64 Rigel R# 64 cleavable linker 64 HCV RESPOND 2 64 optimal dosing 64 null responder HCV 64 PROMACTA 64 C1 INH 64 Fodosine 63 GEM OS2 63 octreotide implant 63 colorectal liver metastases 63 preclinical pharmacokinetic 63 Phase 1a clinical 63 SNT MC# 63 non nucleoside HCV 63 MOZOBIL 63 refractory CLL 63 paclitaxel Taxol ® 63 Squalamine 63 intravesical infusion therapy 63 Dacogen injection 63 alpha folate receptor 63 trodusquemine 63 JAK inhibitors 63 safety tolerability pharmacokinetic 63 TKM PLK1 63 oral methylnaltrexone 63 microplasmin 63 Phase III ADT 63 aflibercept VEGF Trap 63 Pivotal Phase III 63 dacetuzumab SGN 63 mGluR5 NAM 63 lixisenatide 63 Aurora kinase inhibitor 63 PI3K inhibitor 63 EGS# 63 pharmacodynamic profile 63 R roscovitine 63 TYSABRI natalizumab 63 Reverset 63 oxaliplatin Eloxatin 63 antiangiogenic therapy 63 BiTE antibodies 63 MAXY alpha 63 VNP#M 63 MYDICAR 63 GLYX 63 ASONEP 63 ISTODAX 63 tesmilifene 63 EGFR TKI 63 Combination REOLYSIN R 63 vascular disrupting agent 63 S/GSK# 63 refractory AML 63 ThermoDox R 63 CYT# 63 immune modulating 63 drug conjugate 63 epratuzumab 63 BAL# [002] 63 estramustine 63 ASCO GI 63 administered subcutaneously 63 Onconase 63 Listeria vaccine 63 XL# SAR# 63 Dr. Fahar Merchant 63 oral talactoferrin 63 Vascugel 63 MEND CABG II 63 Pharmos proprietary 63 investigational pan BCR 63 double blinded placebo 63 palifosfamide Zymafos TM 63 CB2 selective receptor agonist 63 lymphoid malignancies 63 NeuVax 63 NXL# 63 subcutaneous PRO 63 sunitinib Sutent ® 63 vascular disrupting agents 63 myelofibrosis polycythemia vera 63 ISF# 63 Virulizin R 63 mg/m2 cohort 63 Pivotal Phase 63 dextromethorphan quinidine 63 oral rivaroxaban 63 ANG# 63 Menadione 63 trastuzumab Herceptin ® 63 subcutaneous SC 63 BrachySil TM 63 Talactoferrin 63 tubulin inhibitor 63 oral antiviral 63 NV1FGF 63 Matrix Phase 2b 63 ASG 5ME 63 adalimumab Humira 63 generation URAT1 inhibitor 63 novel anticancer 63 Gastrointestinal Stromal Tumors 63 clinical pharmacology studies 63 Phase #b/#a trial 63 Revimmune 63 DCVax ® Brain 63 OncoGel 63 MGCD# [002] 63 ocular formulation 63 antisense inhibitors 63 Pafuramidine 63 targeting CD# 63 cobiprostone 63 BioNumerik 63 rALLy 63 Relivar 63 lapatinib Tykerb 63 Degarelix 63 ascending dose 63 VA# [002] 63 metastatic castrate resistant 63 hyperphenylalaninemia HPA due 63 PRECISE trial 63 imatinib Gleevec ® 63 DU #b 63 DCVax R 63 Phase IIa clinical trials 63 metastatic colorectal 63 LEUKINE 63 Apaziquone 63 WILEX 63 QLT# 63 HCV protease inhibitors 63 hypoxia activated prodrug 63 Exelixis compounds 63 tiuxetan 63 RAS MAPK pathway 63 herpetic keratitis 63 Cetrorelix 63 Nasulin 63 randomized Phase 2b 63 EGFR HER2 63 Phase 2b Trial 63 oral proteasome inhibitor 63 XL# anticancer compounds 63 Nanobodies ® 63 darapladib 63 canakinumab 63 Vandetanib 63 cetuximab Erbitux R 63 FOLFOX6 63 ENDEAVOR IV 63 MKC# MT 63 AVN# [001] 63 TOLAMBA 63 anticoagulant reversing agent 63 sitaxsentan 63 ZD# [001] 63 PRX # 63 cancer immunotherapies 63 Ophena 63 Cethromycin 63 preclinical efficacy 63 STRIDE PD 63 Dasatinib 63 Telbivudine 63 Ostarine 63 MT#/MEDI-# 63 urate lowering 63 delivers fluocinolone acetonide FA 63 compound AEZS 63 subcutaneous formulation 63 bazedoxifene conjugated estrogens 63 Vidofludimus 63 BENLYSTA TM 63 Ocrelizumab 63 Pharmacokinetics PK 63 ixabepilone 63 trastuzumab emtansine T DM1 63 refractory metastatic 63 MAP# 63 PROVENGE sipuleucel T 63 ruxolitinib 63 5 fluorouracil leucovorin 63 prostone 63 Phase 1b clinical 63 multi kinase inhibitor 63 baminercept 63 multicenter Phase 63 VAPRISOL 63 vandetanib 63 ritonavir boosted 63 Harbor BioSciences 63 Chrysalin 63 phase 2a 63 K ras mutations 63 Debio 63 insulin degludec 63 NEUVENGE 63 ENMD 63 BLP# Liposome Vaccine 63 chemopreventive agent 63 TELCYTA 63 BHT DNA 63 HspE7 63 gefitinib Iressa 63 OMNARIS HFA 63 JAK Inhibitor 63 basal bolus regimen 63 ZEVALIN ® 63 SinuNase ™ 63 FavId 63 Bavituximab 63 LT NS# 63 EXPAREL ™ 63 glucokinase activator 63 squalamine 63 Amigal 63 novel peptide 63 AEGR 63 Targretin 63 pegylated interferons 63 docetaxel chemotherapy 63 LHRH antagonist 63 Daniel Junius 63 Sudhir Agrawal D.Phil 63 AZILECT ® 63 recurrent metastatic ovarian cancer 63 MET inhibitor 63 generation NNRTI 63 telomerase inhibitor drug 63 dasatinib Sprycel 63 Natalizumab 63 Vicriviroc 63 generation purine nucleoside 63 NLX P# 63 alemtuzumab Campath 63 Oracea TM 63 milatuzumab 63 luteinizing hormone releasing 63 pharmacokinetics pharmacodynamics 63 clevidipine 63 YONDELIS R 63 refractory multiple myeloma 63 TLR agonists 63 Pemetrexed 63 AKT inhibitor 63 IgG1 monoclonal antibody 63 anti CD# antibodies 63 aflibercept 63 palifosfamide 63 HRPC 63 GVAX ® 63 Src inhibitors 63 HCV SPRINT 63 Valortim ® 63 predictive biomarkers 63 Shigamabs ® 63 personalized immunotherapy 63 MAA submission 63 adecatumumab MT# 63 Sphingomab 63 Peginterferon 62 cabozantinib 62 initiated Phase Ib 62 antiangiogenic agents 62 midstage trials 62 Copegus ribavirin 62 Protexia R 62 Diabetic Macular Edema 62 Ceflatonin R 62 PEGylated Fab fragment 62 nanopharmaceutical 62 cintredekin besudotox 62 inhaled formulation 62 GSK# [002] 62 carboplatin paclitaxel 62 BiTE antibody 62 BMS# 62 BrachySil 62 ASA# 62 INC# 62 FUSILEV enhances 62 NEUGENE 62 acyclovir Lauriad R 62 Darinaparsin 62 Radezolid 62 XL# [003] 62 stable nucleic acid 62 PREZISTA r 62 HGS ETR1 mapatumumab 62 eculizumab 62 CDP# 62 REMUNE R 62 incyclinide 62 EDEMA3 trial 62 enoximone 62 nucleoside tide 62 thalidomide Thalomid 62 ARRY # 62 sorafenib Nexavar 62 Azedra ™ 62 Antitumor Activity 62 MYCAMINE 62 iclaprim 62 PEGylated irinotecan 62 aleglitazar 62 metastatic sarcomas 62 ToGA 62 AZX# 62 IMPACT DCM 62 EndoTAG 62 BCIRG 62 Initiate Phase 62 NATRECOR R 62 unique alkylating agent 62 Navelbine ® 62 Cinryze ™ 62 bendamustine